Background: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal illness in the developing world. Enterotoxigenic E coli vaccinology has been challenged by genetic diversity and heterogeneity of canonical antigens. Examination of the antigenic breadth of immune responses associated with protective immunity could afford new avenues for vaccine development. Methods: Antibody lymphocyte supernatants (ALS) and sera from 20 naive human volunteers challenged with ETEC strain H10407 and from 10 volunteers rechallenged 4-6 weeks later with the same strain (9 of whom were completely protected on rechallenge) were tested against ETEC proteome microarrays containing 957 antigens. Results: Enterotoxigenic E coli challenge stimulated robust serum and mucosal (ALS) responses to canonical vaccine antigens (CFA/I, and the B subunit of LT) as well as a small number of antigens not presently targeted in ETEC vaccines. These included pathovar-specific secreted proteins (EtpA, EatA) as well as highly conserved E coli antigens including YghJ, flagellin, and pertactin-like autotransporter proteins, all of which have previously afforded protection against ETEC infection in preclinical studies. Conclusions: Taken together, studies reported here suggest that immune responses after ETEC infection involve traditional vaccine targets as well as a select number of more recently identified protein antigens that could offer additional avenues for vaccine development for these pathogens.
Background: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal illness in the developing world. Enterotoxigenic E coli vaccinology has been challenged by genetic diversity and heterogeneity of canonical antigens. Examination of the antigenic breadth of immune responses associated with protective immunity could afford new avenues for vaccine development. Methods: Antibody lymphocyte supernatants (ALS) and sera from 20 naive human volunteers challenged with ETEC strain H10407 and from 10 volunteers rechallenged 4-6 weeks later with the same strain (9 of whom were completely protected on rechallenge) were tested against ETEC proteome microarrays containing 957 antigens. Results: Enterotoxigenic E coli challenge stimulated robust serum and mucosal (ALS) responses to canonical vaccine antigens (CFA/I, and the B subunit of LT) as well as a small number of antigens not presently targeted in ETEC vaccines. These included pathovar-specific secreted proteins (EtpA, EatA) as well as highly conserved E coli antigens including YghJ, flagellin, and pertactin-like autotransporter proteins, all of which have previously afforded protection against ETEC infection in preclinical studies. Conclusions: Taken together, studies reported here suggest that immune responses after ETEC infection involve traditional vaccine targets as well as a select number of more recently identified protein antigens that could offer additional avenues for vaccine development for these pathogens.
Authors: Clayton Harro; Subhra Chakraborty; Andrea Feller; Barbara DeNearing; Alicia Cage; Malathi Ram; Anna Lundgren; Ann-Mari Svennerholm; August L Bourgeois; Richard I Walker; David A Sack Journal: Clin Vaccine Immunol Date: 2011-08-18
Authors: Lisa C Crossman; Roy R Chaudhuri; Scott A Beatson; Timothy J Wells; Mickael Desvaux; Adam F Cunningham; Nicola K Petty; Vivienne Mahon; Carl Brinkley; Jon L Hobman; Stephen J Savarino; Susan M Turner; Mark J Pallen; Charles W Penn; Julian Parkhill; A Keith Turner; Timothy J Johnson; Nicholas R Thomson; Stephen G J Smith; Ian R Henderson Journal: J Bacteriol Date: 2010-08-27 Impact factor: 3.490
Authors: D Huw Davies; Xiaowu Liang; Jenny E Hernandez; Arlo Randall; Siddiqua Hirst; Yunxiang Mu; Kimberly M Romero; Toai T Nguyen; Mina Kalantari-Dehaghi; Shane Crotty; Pierre Baldi; Luis P Villarreal; Philip L Felgner Journal: Proc Natl Acad Sci U S A Date: 2005-01-12 Impact factor: 11.205
Authors: Subhra Chakraborty; Clayton Harro; Barbara DeNearing; Malathi Ram; Andrea Feller; Alicia Cage; Nicole Bauers; A Louis Bourgeois; Richard Walker; David A Sack Journal: Clin Vaccine Immunol Date: 2015-11-18
Authors: Jessica A Harris; Koushik Roy; Virginia Woo-Rasberry; David J Hamilton; Rita Kansal; Firdausi Qadri; James M Fleckenstein Journal: PLoS Negl Trop Dis Date: 2011-12-06
Authors: Yuehui Zhu; Qingwei Luo; Sierra M Davis; Chase Westra; Tim J Vickers; James M Fleckenstein Journal: Infect Immun Date: 2018-10-25 Impact factor: 3.441
Authors: Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores Journal: Clin Microbiol Rev Date: 2022-07-06 Impact factor: 50.129
Authors: F M Kuhlmann; R O Laine; S Afrin; R Nakajima; M Akhtar; T Vickers; K Parker; N N Nizam; V Grigura; C W Goss; P L Felgner; D A Rasko; F Qadri; J M Fleckenstein Journal: Infect Immun Date: 2021-04-16 Impact factor: 3.441
Authors: Subhra Chakraborty; Arlo Randall; Tim J Vickers; Doug Molina; Clayton D Harro; Barbara DeNearing; Jessica Brubaker; David A Sack; A Louis Bourgeois; Philip L Felgner; Xiaowu Liang; Sachin Mani; Heather Wenzel; R Reid Townsend; Petra E Gilmore; Michael J Darsley; David A Rasko; James M Fleckenstein Journal: NPJ Vaccines Date: 2019-08-28 Impact factor: 7.344
Authors: F Matthew Kuhlmann; John Martin; Tracy H Hazen; Tim J Vickers; Madeline Pashos; Pablo C Okhuysen; Oscar G Gómez-Duarte; Elizabeth Cebelinski; Dave Boxrud; Felipe Del Canto; Roberto Vidal; Firdausi Qadri; Makedonka Mitreva; David A Rasko; James M Fleckenstein Journal: PLoS Negl Trop Dis Date: 2019-11-22